In the phase II SUMMIT basket trial (NCT01953926), the pan-HER inhibitor neratinib demonstrated modest activity in HER2-mutant biliary tract cancers, with PFS and OS outcomes comparable to standard therapies, suggesting limited but potential therapeutic relevance in selected patients (Table 3) [73]. This evidence concerns the gene ERBB2 and biliary tract cancer.